Anti-WNT2 monoclonal antibodies increase the activity of DCs in transplanted tumors in CRC mice, significantly improving the therapeutic efficacy of PD-1 antibodies(p = 0.0012) [63]. Here, PDCD1 is linked to colorectal carcinoma.